StimCardio raises $30M to take its wrist-worn AFib therapy into a pivotal trial
Metis MedTech, the family office of John Slump, led the oversubscribed Series A. StimCardio says the money should carry it through a pivotal study and preparation of an FDA De Novo request for its nerve-stimulation wristband.

- Amount
- $30M
- Type
- Series A
- Company
- StimCardio Medical
- Lead investor
- Metis MedTech
- Sector
- Medtech
- Announced
- Oct. 29, 2026
Catheter ablation is an established way to treat atrial fibrillation, StimCardio Medical notes, yet the company says 30% to 40% of patients see the arrhythmia return after a first procedure. StimCardio is building a wristband meant to be worn at home after ablation, and on Oct. 29 it said it had raised $30 million to run a pivotal trial and prepare an FDA filing.
StimCardio said it closed an oversubscribed Series A round led by Metis MedTech, which it identified as John Slump's family office. Catalyst Health Ventures, several corporate strategic investors the company did not name, and other investors, both new and returning, also took part. Slump and Joshua Phillips, managing partner of Catalyst Health Ventures, sit on StimCardio's board. The company did not disclose a valuation.
Why it matters: StimCardio is developing a wearable intended as a therapy for atrial fibrillation, not a monitor, and it is aimed at the large group of patients whose arrhythmia returns after ablation. The company expects the Series A to fund the pivotal study and the FDA filing on which any U.S. sales would depend.
The trial and the filing
The company said the money is expected to carry it through NeuroPulse 2, a planned multicenter pivotal study, and the preparation of a De Novo request to the Food and Drug Administration. De Novo is the FDA's route for new types of low- to moderate-risk devices that have no existing equivalent on the market. NeuroPulse 2 will test whether adding the wearable to catheter ablation improves outcomes over ablation by itself, StimCardio said.
The raise follows NeuroPulse 1, a randomized, double-blind, sham-controlled pilot study. StimCardio said the results were presented at HRX Live 2026 as a late-breaking study and published in the journal Heart Rhythm. The company reported a statistically significant drop in recurrent arrhythmia events among patients who received active stimulation after ablation, compared with the sham group.
"This financing brings together investors with deep expertise in cardiac device innovation," said Amir Soltanianzadeh, StimCardio's chief executive.
How the device is designed
StimCardio's lead product, Rhyvive, is a wristband designed to stimulate the median nerve without breaking the skin, using a closed-loop system that combines physiological sensing with neuromodulation, the company said. It is meant as an add-on to ablation, used at home after the procedure, aiming to cut down on recurrent atrial arrhythmias by acting on autonomic nervous system pathways. U.S. law restricts Rhyvive to investigational use, the release said.
The company cited a 2025 analysis estimating that about 59 million people worldwide live with atrial fibrillation. It noted that the 2023 ACC/AHA/ACCP/HRS clinical guidelines recommend ablation for some patients as a first-line option for rhythm control, and that recurrence has persisted even as ablation methods, pulsed field ablation among them, have advanced.
The lead investor
Metis MedTech describes itself as a platform that invests in and advises medical device companies. According to the release, Slump has been part of four large medical device exits, two of them in cardiac electrophysiology: Farapulse and Atraverse Medical.
What to watch
StimCardio did not say when NeuroPulse 2 will begin enrolling, how many patients or sites it will include, or when it expects to submit the De Novo request. Those dates will set the timeline for any U.S. launch.



